Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) EBIT (2016 - 2026)

Sunshine Biopharma filings provide 13 years of EBIT readings, the most recent being -$1.8 million for Q4 2025.

  • On a quarterly basis, EBIT rose 12.16% to -$1.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.2 million, a 8.05% decrease, with the full-year FY2025 number at -$6.2 million, down 7.14% from a year prior.
  • EBIT hit -$1.8 million in Q4 2025 for Sunshine Biopharma, down from -$1.1 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$279631.0 in Q4 2021 to a low of -$23.4 million in Q4 2022.
  • Median EBIT over the past 5 years was -$1.2 million (2022), compared with a mean of -$2.3 million.
  • Biggest five-year swings in EBIT: tumbled 8255.16% in 2022 and later surged 94.92% in 2023.
  • Sunshine Biopharma's EBIT stood at -$279631.0 in 2021, then tumbled by 8255.16% to -$23.4 million in 2022, then surged by 94.92% to -$1.2 million in 2023, then plummeted by 71.64% to -$2.0 million in 2024, then rose by 12.16% to -$1.8 million in 2025.
  • The last three reported values for EBIT were -$1.8 million (Q4 2025), -$1.1 million (Q3 2025), and -$2.1 million (Q2 2025) per Business Quant data.